SFTPD and serous cystadenocarcinoma: The Kaplan–Meier plotter data, derived from stage-1 and -2 patients, showed a negative ratio between SFTPD expression and either overall or progression-free survival rates of patients with serous cystadenocarcinoma (Figure 6B, p < 0.05).